Radiopharm Theranostics Achieves Primary Endpoint In 90% Of Patients At Second Interim Analysis Of RAD 101 Phase 2B Imaging Trial In Brain Metastases

(MENAFN - GlobeNewsWire - Nasdaq) 90% of patients dosed with RAD 101 and evaluable at interim analysis achieved concordance with MRI imaging (the primary endpoint) First five patients with available ...